Genkyotex’s First in Class NOX Inhibitor GKT137831 to Be Presented at Kidney Week

GENEVA & ARCHAMPS, France--(BUSINESS WIRE)--Genkyotex, the leading developer of NOX inhibitors to treat oxygen-radical mediated diseases, announced today that data from single and multiple dose Phase I studies with the NOX 1 and 4 inhibitor, GKT137831, will be presented at Kidney Week 2012 (San Diego, October 30 – November 4).

The Phase I data will be presented in the Pharmacokinetics (PK)/ Pharmacodynamics (PD) session:

Friday, November 2, 2012, 10.00 AM -12.00 PM

PosterBoard# FR-PO831; Abstract# 2279

Safety and Pharmacokinetics of Single and Multiple Doses of a First in Class Dual NADPH Oxidase 1 and 4 Inhibitor Administered Orally in Health Subjects

Preliminary Phase I results released earlier this year showed that GKT137831 is safe and well tolerated following oral administration of single doses in 36 healthy subjects. Genkyotex plans to advance GKT137831 into a Phase II trial in patients with diabetic nephropathy.

About Genkyotex

Genkyotex is developing first in class, small molecule therapeutics that specifically and selectively inhibit the NOX family of enzymes. Using a unique screening platform, Genkyotex has identified novel NOX inhibitors with the potential to treat disease areas with a high clinical need and large market potential. Genkyotex was founded in 2006 by scientists from Switzerland, the USA and Japan, with backing from Geneva incubator Eclosion. A CHF25 million extension of the Series C investment was closed in July 2012, with existing investors, Eclosion, Edmond de Rothschild Investment Partners, Vesalius BioCapital and MP Healthcare Venture Management all reinvesting. Further information can be found at: www.genkyotex.com.